FDA Issues Class II Recall of Levothyroxine Tablets Across the United States

The U.S. Food and Drug Administration announced a nationwide Class II recall of levothyroxine sodium tablets distributed by Major Pharmaceuticals after testing showed the tablets were subpotent, meaning they delivered less hormone than labeled. The recall covers several dosage strengths (25 µg to 150 µg) packaged in 100‑tablet cartons and 10‑tablet blister packs, with specific lot numbers and expiration dates listed in the FDA notice. The agency classified the recall as Class II because any adverse health effects are expected to be temporary and medically reversible, and the likelihood of serious harm is remote. Patients who take the medication or caregivers are advised to check the lot numbers against the recall list and consult a pharmacist or physician for guidance on replacement therapy.